Manila Bulletin
Sinopharm opts out of COVID-19 vaccine trials in PH; NCR still has highest number of new infections
Chinese pharmaceutical company Sinopharm has withdrawn its plan to conduct Phase 3 clinical trials for its COVID-19 vaccine in the Philippines.
Sinopharm initially expressed interest in both supplying vaccines and conducting trials in the country.
The company has since communicated its continued interest in supplying vaccines but will no longer proceed with clinical trials.
Another Chinese manufacturer, Sinovac, has received approval for clinical trials but still needs ethics clearance.
Russia's Gamaleya Research Institute is also working to find a local partner for its clinical trial application.
The Philippines is actively coordinating with 17 biotech and pharmaceutical companies from seven different countries.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
The Department of Science and Technology (DOST) has started preparations for the COVID-19 vaccine trials in the country.
Read more →
The Philippine Vaccine Expert Panel (VEP), chaired by the Department of Science and Technology, has cleared China's Sinovac COVID-19 vaccine for Phase 3 clinical trials in the country.
Read more →
President Rodrigo R. Duterte announced that the Philippines has secured sufficient funds to purchase coronavirus vaccines once they become available.
Read more →
The World Health Organization (WHO) is urging the Philippines to increase its commitment to the global COVID-19 vaccine trial by pledging more volunteers.
Read more →
The Department of Trade and Industry (DTI) and the Russian embassy are exploring the possibility of establishing a COVID-19 vaccine plant in the Philippines.
Read more →